Focinvez (Fosaprepitant Dimeglumine) Patent Expiration, LOE Window & CMS Spending

Focinvez (Fosaprepitant Dimeglumine) by Steriscience Pte: FDA Orange Book LOE 2039-01-11, 0 AB generics, $224K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSteriscience Pte
FDA Application & PathwayN216686 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-01-11
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$224K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$224K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel